Eight Trending Ingredients, Ranked by How Much Evidence Exists
The ingredients with the loudest year have the thinnest files. The one almost nobody is posting about has three Cochrane reviews.
Eight ingredients have carried this year's skincare conversation. We searched PubMed for human trials on each one, and the ranking came out close to the reverse of the attention. The ingredient with the most published evidence is the one almost nobody is posting about. Two of the eight returned nothing at all.
A search count is a crude instrument, so what follows names the actual studies rather than leaning on the totals.
1. Azelaic acid
The quietest ingredient on the list has the deepest file. Searching for randomized controlled trials on azelaic acid in rosacea and acne returns dozens of records, and more importantly it returns the kind of papers that sit above individual trials: Cochrane systematic reviews of rosacea interventions published in 2004, 2005 and 2011, a 2019 systematic review in the British Journal of Dermatology that graded the evidence, and a 2025 systematic review and meta-analysis of topical rosacea drugs in Actas Dermo-Sifiliográficas.
When several independent teams keep pooling the trials and keep finding an effect, that is a different class of evidence from a single promising study. Azelaic acid is the only ingredient here that has it.
2. Copper peptides
The copper tripeptide GHK-Cu has real literature, most of it about mechanism. A 2026 systematic review in Archives of Internal Medicine Research covers the mechanisms and therapeutic applications, and a 2012 review in Oxidative Medicine and Cellular Longevity set out the case for its role in tissue remodeling.
For topical use on human faces, the clearest study is from 2006 in Archives of Facial Plastic Surgery, which looked at copper tripeptide complex on skin after CO2 laser resurfacing. That is twenty years old and it is a specific population, so hold it accordingly. The mechanism is credible, the human trial base is thin, and both things are true at once.
3. Ectoin
Ectoin, the molecule currently leading the barrier conversation on TikTok, has one good trial. A 2014 randomised comparator-controlled study in Skin Pharmacology and Physiology tested an ectoine-containing cream in mild to moderate atopic dermatitis.
One randomized trial with a comparator is a real result and more than most ingredients on this list can show. It is also one trial, in one condition, which is a long way from the claims being made for it now.
4. PDRN, or salmon DNA
This is the one where the evidence is real and attached to the wrong product. A 2014 phase III trial in the Journal of Korean Medical Science, randomized, double blind, matched pairs, with an active control, tested polydeoxyribonucleotide. That is a serious trial design.
It was an injectable. Searching for topical PDRN trials returns nothing relevant. The serum on the shelf is borrowing the credibility of a needle, and an injected molecule and a molecule in a bottle are two different products with two different questions about whether anything reaches the dermis.
5. Prebiotics and postbiotics
The thinking here has genuinely moved. The framing used to be about balance, and it is now about diversity, which is a better description of what the research is looking at. A 2024 review in the American Journal of Clinical Dermatology covers the skin microbiome for dermatologists, a 2026 review in the British Journal of Dermatology traces the path from prebiotics to engineered microbes in atopic dermatitis, and a 2023 review in the Journal of Cosmetic Dermatology looks at a topical prebiotic in skin aging.
Every one of those is a review. Reviews summarize a field; they are not themselves trials of a product you can buy. The science is moving and the shelf moved faster.
6. Beta-glucan
A 2021 paper in the International Journal of Biological Macromolecules found that oat beta-glucan improved epidermal barrier disruption, working through a specific receptor pathway. That is a proper mechanistic result and it points somewhere.
It is also not a trial in people using a product. Beta-glucan is at the stage where the biology looks plausible and the clinical question has not been asked yet.
7. Exosomes
Exosomes need care, because the honest answer depends on what you mean by the question.
Search exosomes and skin and the literature is large, including a 2026 systematic review and meta-analysis of human clinical trials in Aesthetic Surgery Journal covering exosome-based therapies in aesthetic medicine, and systematic reviews on diabetic wound healing and inflammatory skin disease. That is a real body of work.
Almost none of it is a cosmetic serum you apply at home. Aesthetic-medicine studies generally deliver exosomes with a needle or through microneedling channels, and the wound and disease literature is about damaged or diseased skin rather than healthy skin being maintained. Constrain the search to topical application and the volume collapses to a handful of papers, the earliest from 2025.
So the fair statement is that exosomes have promising evidence for delivery methods that breach the skin, and very little for the bottle. That is the same gap as PDRN, one step behind.
8. Beef tallow
Zero. A search for clinical studies on tallow and skin returns nothing, and a search on the adverse-effect side returns nothing either. There is no published evidence that it works and none that it harms.
The argument for it is that it is natural and close to human sebum. Natural is a description of where something came from rather than a mechanism, and plenty of well-evidenced actives are synthetic while plenty of natural materials irritate skin. It might suit you. There is no literature that will tell you in advance.
What the ranking shows
Attention and evidence are running in opposite directions. The explanation is timing. Evidence takes years and a trend takes weeks, so anything new arrives with its file still mostly empty, while anything with a thick file has been around long enough to be boring.
That has a practical consequence. If you are choosing between an ingredient with three Cochrane reviews and one with two papers from this year, the published evidence tells you something about the odds across many people. What happens on your own face is a separate question.
For that you need your own data, which means comparing yourself against your own baseline over time rather than against a claim. It also means changing one thing at a time, because a routine where four things changed at once cannot tell you which one did the work. The ingredient with the longest evidence record of all, the retinoid, still fails for plenty of people who cannot tolerate it.
FAQ
Which skincare ingredient has the most scientific evidence?
Of the eight trending ingredients reviewed here, azelaic acid has the strongest published base, including Cochrane systematic reviews of rosacea interventions from 2004, 2005 and 2011 and a 2025 systematic review and meta-analysis. Retinoids, which were not part of this comparison, have a deeper record still.
Does beef tallow work on skin?
There is no published clinical evidence either way. A search for studies on tallow and skin returns nothing showing benefit and nothing showing harm. Claims made for it rest on the argument that it resembles human sebum rather than on trials.
Are exosomes proven for skin?
It depends on how they are delivered. A 2026 systematic review and meta-analysis in Aesthetic Surgery Journal covers human clinical trials of exosome therapies in aesthetic medicine, where they are usually injected or delivered through microneedling. Evidence for exosomes in a topical product you apply at home is far thinner, and the earliest studies date from 2025.
Is PDRN the same in a serum as in an injection?
No. The strong trial evidence for polydeoxyribonucleotide, including a 2014 phase III study, used an injectable. Topical PDRN has not been tested in the same way, and whether a molecule of that size crosses the skin barrier is a separate question from whether it works once it is in the dermis.
What replaced the idea of microbiome balance?
Diversity. The research has shifted from describing the skin microbiome as balanced or unbalanced toward measuring how varied the microbial community is. The published work on topical prebiotics and postbiotics is currently dominated by reviews rather than product trials.